01
Measure
EEG records the user’s brain activity as an electrical signal. It supplies feedback to the research system during stimulation.
EEG FEEDBACKBIOELECTRONICS. ARTIFICIAL INTELLIGENCE. HUMAN POSSIBILITY.
A new current
in chronic pain research.
We’re investigating chronic pain with a closed-loop bioelectronic system. AI analyzes EEG feedback to optimize the alternating current (AC) delivered through skin-surface electrodes.
The Biocurrent system is investigational, is not FDA-cleared or approved, and is not available for commercial sale. Safety and effectiveness have not been established.
EEG FEEDBACK. AI-GUIDED CURRENT.FIG. 01
Conceptual illustration
Not patient data
Not patient data
COMPANY-REPORTED STUDY
Puerto Vallarta, Mexico
280study participants
697reported study sessions
Randomized.
Double-blind.Sham-controlled study
Double-blind.Sham-controlled study
Behind every data point,
there’s a person.
A walk with a friend. A full day at work. A quiet night. Chronic pain can change the shape of ordinary life. That is why better questions, and carefully designed research, matter.
02 / THE SCIENCE
EEG informs the AI.
AI shapes the current.
Biocurrent uses the user’s EEG signal as feedback to adjust electrical stimulation. That ongoing link between measurement and current delivery makes it a closed-loop system.
02
Adapt
AI analyzes the EEG signal and adjusts the delivered current in response. The aim is to optimize stimulation using that feedback; clinical benefit remains under investigation.
AI-GUIDED CURRENT03
Deliver
Alternating current (AC) is delivered through electrodes on the skin near the spine or the area of chronic pain. EEG feedback guides further current adjustments, completing the loop.
AC THROUGH SURFACE ELECTRODESOur research focus is chronic pain. Biocurrent delivers electrical stimulation through electrodes, not a listening therapy. Safety and effectiveness have not been established.
03 / CLINICAL RESEARCH
Curiosity starts it.
Evidence moves it forward.
Our company-reported Phase II study is a starting point for deeper scientific review. We invite the questions that make the next study stronger.
COMPANY-REPORTED · PHASE IISTUDY 01
Designed to ask
a meaningful question.
The study compared AI-guided stimulation with a fixed-waveform control using the same hardware, according to Biocurrent’s study summary.
Study design
- Design
- Randomized, double-blind, sham-controlled
- Participants
- 280 total · 190 active / 90 control
- Study visits
- 1–3 sessions · 30 minutes per session
- Setting
- Single center · Puerto Vallarta, Mexico
- Measure
- Self-reported pain, 0–10 numerical rating scale
Research context matters. These are company-reported findings from one short study, not established safety or effectiveness. A public registry identifier and peer-reviewed publication are not linked here. Request the protocol, manuscript, and analysis details for due diligence.
REPORTED OBSERVATIONS
Both groups.
The same scale.
Descriptive figures reproduced from the company’s existing study summary. Active and control results are shown together.
Active · n=190Control · n=90
Mean cumulative pain-score reduction
Active84.0%
Control51.7%
Participants reporting ≥50% cumulative reduction
Active93.2%
Control57.8%
0–100% scale. “Cumulative” follows the company summary’s terminology across up to three sessions. These figures do not establish long-term benefit or superiority to other treatments.
Read the research summary & downloads
View the reported outcomes table
| Outcome | Active | Control |
|---|---|---|
| Baseline pain score (0–10) | 6.28 | 6.00 |
| First-session mean reduction | 68.3% | 33.5% |
| Cumulative mean reduction | 84.0% | 51.7% |
| Final mean pain score (0–10) | 0.99 | 3.00 |
| Participants with ≥50% cumulative reduction | 93.2% | 57.8% |
| Participants reporting a final pain score of zero | 51.1% | 17.8% |
| Reported device-related adverse events | 0 | 0 |
The company summary reports 697 total study sessions and no device-related adverse events during the observation period. This does not establish safety or rule out uncommon, delayed, or unobserved risks. A final pain score of zero does not establish a cure or lasting resolution.
What these observations can and cannot tell us
The reported differences warrant careful review and further investigation. They do not establish effectiveness, durability, or generalizability. The control group also reported substantial changes in pain scores.
This was a single-center study with up to three sessions per participant. Interpretation requires the full protocol, analysis plan, missing-data handling, masking assessment, confidence intervals, adverse-event definitions, and follow-up information. The public summary does not include those underlying materials. Prospective collaborators and investors should review them with the study team.
The study did not compare Biocurrent with medicines, implanted devices, or other marketed treatments. “Phase II” is the company’s study designation and does not indicate FDA authorization or endorsement.
Review the source and request study materials
Source: Biocurrent’s company-provided summary titled Efficacy and Safety of a Closed-Loop, AI-Modulated, EEG-Guided Non-Invasive Bioelectronic Neuromodulation Device for Pain: A Double-Blind, Randomized, Sham-Controlled Phase II Trial (n=280, Puerto Vallarta, Mexico), as reproduced on the prior company website.
The title describes the study’s subject, not an established safety or effectiveness conclusion. This page is a summary, not a publication of the full study. Contact the study team for publication status, registration information, and ethics documentation. This summary does not imply regulatory acceptance.
Request the research materials04 / FROM SIGNAL TO SYSTEM
Real hardware.
A question still being explored.
A closer look at the Biocurrent V6. These photographs show our current device in development, with its two labeled channels, front-panel control, and power and BLE indicators.
BIOCURRENT V6 · INVESTIGATIONAL
Made tangible.
Engineering is where an idea meets the details. Explore the device from the workbench to the front panel.
Actual device photographs supplied by Biocurrent. The pictured V6 is not presented as the specific hardware used in the reported study. Not FDA-cleared or approved. Not available for commercial sale.
05 / THE WORK AHEAD
The next chapter
deserves the right people.
Our ambition is to advance the research responsibly. That calls for patient capital, scientific challenge, and experience turning complex technology into carefully evaluated medical devices.
Ask the next
clinical questions.
Plan further studies to examine reproducibility, durability, and the questions that short-term observations leave open.
Build toward
regulatory review.
Develop the evidence, quality systems, and technical documentation needed to support an appropriate regulatory pathway.
Bring rigor
to every layer.
Continue hardware, software, and human-factors development with experienced engineering and clinical collaborators.
These are development objectives, not promised milestones. Any future commercialization depends on the required regulatory authorizations, further evidence, financing, and execution. No submission, clearance, approval, or launch date is promised.
06 / OUR PEOPLE
Different disciplines.
A shared sense of purpose.
Experience across software, hardware, clinical operations, and capital markets. A team built to keep asking better questions.
Andrew Blount
Founder & CEOTechnology entrepreneur and former RealPage EVP. Founded Biocurrent in 2020, motivated by his own experience with chronic pain.
LinkedInQN
Quynh Nguyen
Chief Technology OfficerLeads hardware and software engineering, including collaboration with the company’s development and testing partners in Vietnam.
Dereck Villaseñor Toríz
Clinical Trial DirectorLeads the company’s clinical study operations in Puerto Vallarta, Mexico.
Sharon Pollack
VP of Market DevelopmentBrings experience in events and donor development with Barrow Neurological and the St. Joseph’s Hospital Foundation.
BOARD OF DIRECTORS
Alfred R. Berkeley III
Former President of Nasdaq, bringing experience in capital markets and public-company leadership.
OUR ORIGIN
It began with
a personal question.
Andrew’s experience with chronic pain set this work in motion. His background in software and early neural-network experiments shaped the question: could a system learn from the body as it goes?
That personal motivation is the origin of the research. Clinical evidence must stand on its own.
Meet the founder07 / AN OPEN INVITATION
Good questions welcome.
Great minds, too.
We’re connecting with people who see the value of asking difficult questions, building carefully, and following the evidence.
010203
Invest in the next questions.
Explore the company, development priorities, and research materials through a due-diligence conversation.
Help us think further.
Bring expertise in neuromodulation, clinical research, regulatory strategy, quality, or medical-device development.
Build the evidence together.
Start a conversation about research collaboration, study design, engineering, or future clinical investigation.
A conversation starts here.ablount@biocurrent.com
LET’S BEGIN
What brings you here?
Tell us a little about yourself and the conversation you’d like to have.
A good place to start.
Your inquiry has been received. The team will follow up at the email you provided.